Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US21833P3010
Corbus Pharmaceuticals Holdings, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -85.31 m USD |
| EBIT | -157.07 m USD |
| Net income | -78.54 m USD |
| Diluted EPS – continuing operations | -5.90 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
More stocks
- Sajodongaone Co Ltd (008040.KS)
- NFC Corporation (265740.KQ)
- Dong A Eltek Co. Ltd (088130.KQ)
- MHP Hotel AG (CDZ0.DE)
- OPPSTAR (0275.KL)
- Austco Healthcare Ltd (AHC.AX)
- Venu Holding Corp (VENU)
- Hoffmann Green Cement Technologies (ALHGR.PA)
- Adtraction Group AB (ADTR.ST)
- Fuzetec Technology Co Ltd (6642.TWO)
- Stabilis Solutions, Inc. (SLNG)
- EBR Systems, Inc. (EBRCZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.